The survival benefit of adjuvant radiotherapy for pathological T4N2M0 colon cancer in the Modern Chemotherapy Era: evidence from the SEER database 2004–2015
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 48 (1), 834-840
- https://doi.org/10.1080/21691401.2020.1770270
Abstract
Neoadjuvant chemoradiotherapy has been established as the standard treatment for patients with locally advanced rectal cancer. However, the role of radiotherapy (RT) has not been fully confirmed in advanced colon cancer (LACC). We postulated that patients with pathological T4N2 locally advanced colon cancer would benefit more from RT. 6715 pT4N2M0 colon cancer patients were included in the Surveillance, Epidemiology, and End Results (SEER) database. The primary endpoints were 5-year overall survival (OS) and cancer-specific survival (CSS). Propensity score matching (PSM) with Kaplan–Meier and Cox proportional hazards’ models was performed to estimate prognosis. Before PSM, patients underwent RT had better OS and CSS as compared to patients did not receive RT (OS: 40.1% vs 27.6%, p < .001; CSS: 49.6% vs 41.1%, p = .002). After PSM, 239 matched pairs were formed for further analysis. RT group also presented significantly improved prognosis (OS: 40.1% vs 25.7%, p = .008; CSS: 49.6% vs 38.2%, p = .042). Multivariable Cox regression analysis showed that RT was a protective factor [OS:Hazard ratio (HR) =0.677, 95% Confidence interval (CI): 0.532–0.862, p = .002; CSS: HR = 0.708, 95% CI: 0.533–0.941, p = .018]. For pT4N2M0 colon cancer patients, the addition of RT seems to confer survival benefit as compared to patients who did not receive RT.Keywords
This publication has 20 references indexed in Scilit:
- Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trialThe Lancet Oncology, 2014
- What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?European Journal of Cancer, 2012
- Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: A single institution experienceEuropean Journal of Surgical Oncology, 2012
- Prognostic Value of the Lymph Node Ratio in Stage III Colorectal Cancer: A Systematic ReviewAnnals of Surgical Oncology, 2010
- Multivisceral Resection for Colon CarcinomaDiseases of the Colon & Rectum, 2009
- The TME Trial After a Median Follow-up of 6 YearsAnnals of Surgery, 2007
- Lymph Node Evaluation and Survival After Curative Resection of Colon Cancer: Systematic ReviewJNCI Journal of the National Cancer Institute, 2007
- Population-Based Assessment of the Surgical Management of Locally Advanced Colorectal CancerJNCI Journal of the National Cancer Institute, 2006
- Phase III Study of Adjuvant Chemotherapy and Radiation Therapy Compared With Chemotherapy Alone in the Surgical Adjuvant Treatment of Colon Cancer: Results of Intergroup Protocol 0130Journal of Clinical Oncology, 2004
- Adjuvant postoperative radiotherapy for colon carcinomaCancer, 2004